What is Repligen?
Repligen is a bioprocessing technology company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Bioprocessing technology company
- Headquarters
- Waltham, United States
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: RGEN
What is Repligen?
Repligen is a bioprocessing technology company company headquartered in Waltham, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Repligen is a bioprocessing technology company company headquartered in Waltham, United States. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Repligen should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Repligen offer?
Repligen's profile centers on Bioprocessing systems, Filtration, Chromatography, Analytics.
- Bioprocessing systems· Bioprocessing technology company
- Filtration· Bioprocessing technology company
- Chromatography· Bioprocessing technology company
- Analytics· Bioprocessing technology company
- Single-use systems· Bioprocessing technology company
- Biopharma manufacturing· Bioprocessing technology company
How does Repligen make money?
Repligen makes money through commercial activity tied to bioprocessing technology company.
Repligen monetizes through the model common to bioprocessing technology company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Repligen?
Repligen's named executives should be verified on the official leadership or investor-relations page before outreach.
- Repligen executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Repligen finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Repligen operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Repligen's leadership?
Repligen should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.repligen.com- Repligen investor relationsInvestor relations / corporate contactcontact via https://www.repligen.com
How is Repligen funded?
Repligen's current status is Public company; Nasdaq: RGEN.
Repligen's capital profile is best understood through its current public-company status: Public company; Nasdaq: RGEN. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Repligen get here?
Repligen's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingRepligen is foundedThe company begins building in bioprocessing technology company.
- Scale-upCommercial footprint expandsRepligen broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: RGENPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Repligen's competitors?
Repligen competes with larger incumbents and focused specialists in bioprocessing technology company.
Repligen — frequently asked questions
